Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
JNJ-10450232/ Not yet marketed · 1 trial · 1 indication
Time-weighted sum of pain intensity difference by first multiplying each pain intensity difference (PID) score by the time from the previous time point, and adding them together for each scheduled time point within 0-6 hours. Time points included 15 minutes, 30 minutes, 45 minutes, 1 hour, 1.5 hours, 2 hours, 3 hours, 4 hours, 5 hours, and 6 hours. The minimum SPID 0-6 was -30 and the maximum SPID 0-6 was 60, where higher is better. Pain intensity is the amount of pain experienced on a scale of 1-10 (where 1=no pain and 10=very severe pain).
| Arm | Type | Description |
|---|---|---|
| JNJ-10450232 250 mg | EXPERIMENTAL | - |
| JNJ-10450232 1000 mg | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | - |
| Acetaminophen 1000 mg | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| JNJ-10450232 / Not yet marketed | DRUG | Subjects who meet the randomization criteria at baseline within 4.5 hours after dental surgery will be assigned to one of four treatment groups stratified by pharmacokinetic blood sampling schedule and by baseline pain intensity level. |
| acetaminophen / Tylenol | DRUG | Subjects who meet the randomization criteria at baseline within 4.5 hours after dental surgery will be assigned to one of four treatment groups stratified by pharmacokinetic blood sampling schedule and by baseline pain intensity level. |
Inclusion Criteria: * Subjects aged 18-45 years * At least moderate dental pain assessed by a categorical scale pain intensity scale and a score of at least 5 on the 11-point (0-10) pain intensity numerical rating scale (PI-NRS) following surgical removal of three third-molars Exclusion Criteria: ...
JNJ-10450232 is an investigational small molecule being developed for the treatment of pain. It is currently in Phase 2 clinical development and has been studied in a completed trial for pain management.
The molecular target of JNJ-10450232 has not been disclosed. It is a small molecule being studied for its pain-relieving effects, but its specific mechanism of action is not publicly available.
JNJ-10450232 is being developed by Johnson & Johnson, a multinational pharmaceutical company traded on the New York Stock Exchange under the ticker symbol JNJ.
JNJ-10450232 is in Phase 2 clinical development. It is an investigational drug and has not yet been approved by regulatory authorities. One Phase 2 trial has been completed.
JNJ-10450232 has been studied in one completed Phase 2 clinical trial, NCT02209181, titled 'A Dental Pain Study to Test the Effectiveness of a New Pain Reliever Medicine.' The trial enrolled 269 male participants aged 18 years and older in the United States.
No alternative names for JNJ-10450232 have been disclosed. It is identified solely by its investigational code and is not known to be marketed under any other name.